COMP <GO>
VIR vs MESO // EV/EBITDA & P/E VALUATION
Vir Biotechnology Inc. (NASDAQ) VS. Mesoblast Limited (NASDAQ) • 15-METRIC TALLY: VIR 0
— MESO 2
■ METRIC PARITY
LAST: $11.75 (-1.51%) • MKT CAP: $2.01B
valuation
—
LAST: $15.67 (+17.03%) • MKT CAP: $2.04B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VIR VS. MESO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VIR | MESO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -19.74% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -7.60% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.40 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 58.6 | -4.80 | MESO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.01B | $2.04B | -$29.4M | MESO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VIR REV | MESO REV | VIR GROSS % | MESO GROSS % | VIR FCF | MESO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $68.6M | — | 98.0% | — | -$396.6M | — |
| FY 2024 | $74.2M | — | 98.0% | — | -$453.7M | — |
| FY 2023 | $86.2M | — | — | — | -$778.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VIR // BETA —
MESO // BETA —